trial · primary record
REM-422
Myelodysplastic Syndromes
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2028-03-30 |
| Primary endpoint | Frequency and severity of Treatment Emergent Adverse Events (TEAEs) |
| Registry ID | NCT06297941 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:34.670Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06297941
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.